Polaris Market Research today announced findings from its latest report, projecting the global aptamers market to grow from USD 2.9 billion in 2024 to USD 16.33 billion by 2032, registering a CAGR of 24.1% during the forecast period. Growing research into aptamer-based diagnostics and therapeutics, increasing prevalence of chronic and rare diseases, and the potential advantages of aptamers compared with antibodies are supporting market expansion.

Key Growth Drivers, Major Companies and Segments Covered

Growth Drivers: Aptamers are short, single-stranded DNA or RNA molecules that can selectively bind to target molecules with high affinity and specificity. Their small size, stability, and potential for lower immunogenicity compared with antibodies have contributed to increasing interest among researchers and biotechnology companies.

Aptamers are being investigated for diagnostic, therapeutic, and research applications. Their potential use in disease detection and targeted therapies is encouraging companies and research institutions to develop new aptamer-based technologies.

The growing prevalence of chronic and rare diseases is also supporting research into new therapeutic approaches. Increasing investment in biotechnology research and development is creating additional opportunities for the commercialization of aptamer technologies.

Major Companies Covered:

• Base Pair Biotechnologies
• SomaLogic
• Aptadel Therapeutics
• Aptamer Group
• Noxxon Pharma
• Aptagen
• TriLink Biotechnologies
• Altermune
• Vivonics
• AM Biotechnologies

Segments Covered: By Type, the market includes Nucleic Acid Aptamers and Peptide Aptamers. By Application, it covers Diagnostics, Therapeutics, Research and Development, and Others. Regional analysis includes North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.

Browse More Information:

https://www.polarismarketresearch.com/industry-analysis/aptamers-market 

Market Dynamics and Segment Highlights

The nucleic acid aptamer segment accounted for the largest market share in 2022. Nucleic acid aptamers are being investigated for applications including age-related macular degeneration and other diseases.

Macugen, developed by Eyetech Pharmaceuticals, is identified by Polaris as the only FDA-approved therapeutic aptamer currently available. Its use in neovascular age-related macular degeneration has demonstrated the potential of aptamer-based therapeutics and encouraged further research.

The peptide aptamer segment is projected to witness strong growth because of its applications in diagnostics and therapeutics. Researchers have also explored peptide aptamers in biosensor technologies, including applications related to cardiovascular disease diagnostics.

Recent Developments in the Aptamers Market

In January 2023, Aptamer Group collaborated with BaseCure Therapeutics to develop optimer-targeted therapies.

In April 2020, Achiko entered into a partnership with Pengurus Wilayah Nahdlatul Ulama DKI for marketing its aptamer-based COVID-19 kit, AptameX.

The industry continues to see product-development efforts, research collaborations, partnerships, and commercialization initiatives as companies work to improve aptamer affinity, stability, specificity, and potential clinical applications.

Regional Snapshot: North America Leads, Asia Pacific Fastest-Growing

North America dominated the aptamers market in 2022. The region benefits from established healthcare infrastructure, significant research activity, chronic-disease burden, and the presence of biotechnology and pharmaceutical companies working on aptamer applications.

Asia Pacific is expected to register the fastest growth during the forecast period. Increasing investments by market participants, expanding research activity, growing awareness of aptamer-based products, and a large patient population are supporting the region's development.

The COVID-19 pandemic increased scientific interest in technologies capable of targeting viral proteins and host-cell receptors. Researchers explored aptamers for potential diagnostic and therapeutic applications, contributing to greater visibility for the technology.

Why It Matters for Biotechnology and Healthcare Stakeholders

For biotechnology companies, pharmaceutical manufacturers, diagnostic developers, research institutions, investors, and healthcare technology companies, the aptamers market provides insight into emerging molecular technologies and their potential applications. Monitoring developments in diagnostics, therapeutics, research, and commercialization can help stakeholders understand the evolving competitive landscape.

Conclusion

The global aptamers market is expanding rapidly as research advances in molecular diagnostics and targeted therapeutics. With revenue projected to reach USD 16.33 billion by 2032 at a CAGR of 24.1%, continued R&D investment, development of aptamer-based products, strategic collaborations, and growing activity across Asia Pacific are expected to remain important factors shaping the market.

More Trending Latest Reports By Polaris Market Research:

Semiconductor Intellectual Property Market

Botulinum Toxin Market

Drone Software Market

Colorants Market

Fingerprint Sensor Market

Livestock Monitoring Market

Livestock Monitoring Market

Drone Software Market

Alpha-Gal Syndrome Allergy Market